Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neurobeachin (NBEA)
- Target
- NBEA
- Molecular classification
- Other (BEACH domain-containing scaffolding/trafficking protein), A-kinase anchoring protein (AKAP), Multidomain cytosolic protein
01
Overview
Neurobeachin (NBEA) is a large, neuron-specific, multidomain protein containing a BEACH domain and functioning as a key scaffolding and trafficking molecule at excitatory and inhibitory synapses[1][2][3][4][5]. It serves as an A-kinase anchoring protein (AKAP), localizing protein kinase A to specific subcellular sites and regulating activity-dependent plasticity by controlling the targeting, surface expression, and internalization of major neurotransmitter receptors (notably AMPA, NMDA, and GABA_A receptors)[1][2][3][4]. NBEA is essential for both the formation and maintenance of synapses, postsynaptic density composition, and vesicle trafficking[2][3][4]. Human genetic studies implicate mutations in NBEA in epilepsy, autism spectrum disorder, and intellectual disability[5]. Its dysfunction leads to severe neurological phenotypes and synaptic deficits but, as an intracellular scaffolding protein, it is not currently considered a direct therapeutic target.
- Other names
- BCL8BKIAA1544LYST2FLJ10197Lysosomal-trafficking regulator 2Protein BCL8BNEDEGE
02
Mechanism of action
Not applicable; there are no drugs currently targeting this protein.
03
Biological functions
Synaptic receptor trafficking (regulates postsynaptic targeting and internalization of neurotransmitter receptors)Vesicle trafficking and membrane protein targeting (particularly at the trans-Golgi network and postsynaptic membranes)Regulation of synaptic structure and function (dendritic spine formation, synaptogenesis, synaptic plasticity)Anchoring protein kinase A (PKA) at synaptic sitesRegulation of synaptic transmission
04
Disease associations
Neurodevelopmental disorders (notably autism spectrum disorder and intellectual disability)EpilepsyNeuromuscular transmission disorders (lethal phenotype in knockout mice due to neuromuscular synapse failure)Potential relevance in overweight/obesity and multiple myeloma (through gene disruption)
05
Safety considerations
Complete loss of function is lethal in mice due to severe deficits in synaptic transmissionHaploinsufficiency or heterozygous mutations cause neurodevelopmental disease but direct therapeutic targeting is likely to have significant neurotoxic risk
06
Interacting drugs
None identified
07
Biomarkers
Potential candidate biomarker for neurodevelopmental disease risk or diagnosis (genetic variants in NBEA associated with epilepsy, ASD, and intellectual disability)
Beyond the preview
Go deeper on Neurobeachin (NBEA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurobeachin (NBEA).